Anxiety and GLP-1 Drugs: What We Know
GLP-1 receptors are expressed throughout the brain, including in regions that regulate mood, anxiety, and reward processing. The GLP-1 system has been studied for its effects on stress responses and anxiety-like behaviors in animal models, with some studies showing that GLP-1 receptor activation reduces anxiety and others showing neutral or mixed effects. In retatrutide, the additional GIP and glucagon receptors add complexity. Reddit users have reported both improvements and worsening of anxiety symptoms, but these reports are anecdotal and should be interpreted cautiously.
Clinical Trial Data on Anxiety
The retatrutide clinical trials — Phase 2 published in NEJM 2023 and Phase 3 TRIUMPH results — have not reported anxiety as a treatment-emergent adverse event occurring at rates above placebo. Anxiety is not listed in the standard adverse event tables for either trial. This suggests that if retatrutide does affect anxiety, the effect is not common enough or severe enough to reach statistical significance in controlled trials. However, clinical trials exclude participants with significant psychiatric conditions, so the data may not capture the full range of anxiety experiences across all potential users.
The Indirect Mechanisms
Retatrutide could affect anxiety through several indirect mechanisms. The heart rate increase of 2-5 bpm could be perceived as physical anxiety symptoms by some users, particularly those prone to anxiety. The reduced appetite and food intake — which can affect blood sugar stability — could also influence mood. On the positive side, significant weight loss often improves body image, self-esteem, and overall mental health, which could reduce anxiety. The net effect likely depends on the individual and their specific circumstances. Anyone with a history of anxiety disorders should discuss potential effects with their healthcare provider before using retatrutide.
Leave a Reply